U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07525635) titled 'Aspirin Dosing in Pregnancy' on April 01.
Brief Summary: The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Study Start Date: April 15
Study Type: INTERVENTIONAL
Condition:
Preeclampsia Possible
Intervention:
DRUG: Aspirin
81mg twice a day (162mg total)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: NYU Langone Health
Disclaimer: Curated by HT Syn...